Form 4: Syndax Pharmaceuticals CFO Keith A. Goldan Increases Stake in Company
SEC Form 4
Keith A. Goldan, CFO of Syndax Pharmaceuticals, recently purchased 3,000 shares of the company's common stock.
Summary
- On May 19, 2025, Keith A. Goldan, the Chief Financial Officer of Syndax Pharmaceuticals Inc. (SNDX), acquired 3,000 shares of common stock.
- The shares were purchased at prices ranging from $8.8465 to $9.2825.
- Following the transaction, Goldan directly owns 93,746 shares of Syndax Pharmaceuticals.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CFO's purchase suggests confidence, but it's a relatively small transaction.
Positives
- The CFO's purchase of company stock could be interpreted as a sign of confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive signal, suggesting that a company insider believes the stock is undervalued or that the company's prospects are strong. However, it's just one data point and should be considered alongside other factors when evaluating a company.
Stakeholder Impact
- The stock purchase could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/19/2025 | Date of the transaction: Keith A. Goldan purchased 3,000 shares of Syndax Pharmaceuticals. |
Keywords
Syndax Pharmaceuticals, SNDX, Keith A. Goldan, CFO, stock purchase, Form 4, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.